Claire Henchcliffe

New Capabilities

As of May 2026: Leading Phase I embryonic stem cell trial for Parkinson's; presenting 36-month safety and efficacy data

For more than 50 years, Parkinson's disease treatment has meant managing symptoms with medication—not addressing the root cause: the death of dopamine-producing brain cells. Now, clinical trials are testing whether stem cell therapies can actually replace those lost neurons.

Updated May 27